Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cellophil (TM) is particularly designed for optical lenses, drug delivery and also may be used as additive for food and cosmetics or as fiber for fabrics. More
New Active Ingredient + Innovative Drug Delivery System = Business Success More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
A liquid system which enables rapid transmigration of therapeutic doses of up to large molecules More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
This ORS effervescent tablet has been developed according to the latest guidelines of the WHO. We are looking for partners in Europe and in other areas to commercialize the ORS effervescent tablets More
The development of a transdermal therapeutic system offers the advantages of constant plasma levels i.e. avoiding of plasma peaks and providing of therapeutic plasma level during the early morning hours More
Adhesive patch containing and delivering essential and balsamic oils for the symptomatic treatment of the common cold and nasal congestion More
Multilayered controlled release oral solid pharmaceutical composition in tablet form suitable for oral administration comprising at least two layers containing active material in association with excipients and additives. More
LPCN 1035 is being developed as a longer acting version of a leading respiratory product, specifically as a non-sedating, non-narcotic anti-tussive. More
Your selection
Browse By
- Industry sector
- Intravesical
- Nasal
- Nasal topical
- Ophthalmic
- Oral liquid
- Oral solid
- Otic
- Parenteral
- Pulmonary
- Rectal
- Systemic
- Topical
- Vaginal
- Therapeutic target
- Adult respiratory distress syndrome
- Allergy, respiratory
- Asthma
- Asthma, bronchospasm
- Bronchitis
- Chest disorder (other)
- Chlamydia pneumoniae
- Chronic obstructive pulmonary disease
- Cough
- Cystic fibrosis
- Dysplasia, bronchopulmonary
- Emphysema
- Granulomatous lung disease sarcoidosis
- Idiopathic respiratory distress syndrome
- Meconium aspiration syndrome
- Nasal disorder (other)
- Obstructive airway disease
- Pneumonia
- Pneumonocystis carinii lung infection
- Pseudomonas lung infection
- Respiratory disorder (other)
- Respiratory syncytial virus
- Respiratory tract infections
- Rhinitis
- Rhinovirus (common cold)
- Sinusitis
- Sleep apnea
- Throat disorder (other)
- Tuberculosis
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us